Schoenberg Evan D, Chaudhry Amina L, Chod Ross, Zurakowski David, Ayyala Ramesh S
*Department of Ophthalmology, Tulane School of Medicine, Tulane University, New Orleans, LA †Departments of Anesthesia and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA.
J Glaucoma. 2015 Sep;24(7):543-9. doi: 10.1097/IJG.0000000000000023.
To compare operative outcomes of patients after phacocanaloplasty and phacotrabeculectomy through 12 months' follow-up.
Retrospective, nonrandomized, comparative case series.
We included 36 eyes of 36 patients with open-angle glaucoma who underwent combined phacoemulsification and canaloplasty (phacocanaloplasty) and 41 eyes of 41 patients with open-angle glaucoma who underwent combined phacoemulsification and trabeculectomy with mitomycin C (phacotrabeculectomy) with 12 months' of postoperative follow-up. All surgeries were performed by a single surgeon (R.S.A.) between January 2007 and May 2011.
Failure was based on intraocular pressure (IOP; >18 or <4 mm Hg at 1 y), second operative procedure (any eye requiring reoperation), or decrease in visual acuity by 0.20 logMAR. Change in IOP, visual acuity (VA), glaucoma medications, and complication rates at 12 months were analyzed.
There were no differences in demographics other than the sex between the groups. There were also no significant differences in previous surgery or in preoperative VA, IOP, or use of glaucoma medications between the groups, though the phacotrabeculectomy group had a higher preoperative IOP at baseline and a larger SD. Both groups showed significant reduction in IOP from baseline at every time point (P<0.001). No significant difference in mean IOP at 12 months was found, with a mean of 14.1±4.4 mm Hg in the phacocanaloplasty group and 11.8±5.4 mm Hg in the phacotrabeculectomy group (P=0.07). The phacotrabeculectomy group showed a significantly greater median absolute (8 vs. 5 mm Hg) and percent (40% vs. 28%) reduction in IOP at 12 months (P=0.02). Postoperative glaucoma medication use was similar between the 2 groups.Overall failure rates at 1 year were comparable between the 2 groups: 22% for phacocanaloplasty versus 20% for phacotrabeculectomy (P=0.79). Phacotrabeculectomy eyes experienced more visual failures (5% vs. 0%, P=0.50), whereas phacocanaloplasty experienced more IOP failures (17% vs. 12%, P=0.75). No difference in operative failure rate was found between the phacocanaloplasty and phacotrabeculectomy groups (6% vs. 5%, P=1.00) and this held after controlling for covariates. Final VA was not statistically different between the 2 groups.
Phacocanaloplasty and phacotrabeculectomy both achieved significant reduction in IOP and improvement in VA at 12 months with comparable success rates. Phacotrabeculectomy achieved a statistically greater median percentage decrease in IOP, but the 2 procedures resulted in comparable mean IOP at 12 months.
通过12个月的随访比较晶状体睫状体沟切开术和小梁切除术患者的手术效果。
回顾性、非随机、对照病例系列研究。
我们纳入了36例开角型青光眼患者的36只眼,这些患者接受了白内障超声乳化联合睫状体沟切开术(晶状体睫状体沟切开术),以及41例开角型青光眼患者的41只眼,这些患者接受了白内障超声乳化联合丝裂霉素C小梁切除术(小梁切除术),并进行了12个月的术后随访。所有手术均由同一位外科医生(R.S.A.)在2007年1月至2011年5月期间完成。
失败的定义为眼压(IOP;1年后>18或<4 mmHg)、二次手术(任何需要再次手术的眼)或视力下降0.20 logMAR。分析12个月时眼压、视力(VA)、青光眼药物使用情况及并发症发生率的变化。
两组患者除性别外,人口统计学特征无差异。两组患者既往手术史、术前视力、眼压或青光眼药物使用情况也无显著差异,不过小梁切除术组基线时术前眼压较高,标准差较大。两组在每个时间点的眼压均较基线显著降低(P<0.001)。12个月时平均眼压无显著差异,晶状体睫状体沟切开术组平均眼压为14.1±4.4 mmHg,小梁切除术组为11.8±5.4 mmHg(P=0.07)。小梁切除术组在12个月时眼压的中位数绝对降低值(8 vs. 5 mmHg)和百分比降低值(40% vs. 28%)显著更大(P=0.02)。两组术后青光眼药物使用情况相似。两组1年时的总体失败率相当:晶状体睫状体沟切开术组为22%,小梁切除术组为20%(P=0.79)。小梁切除术组的视力失败更多(5% vs. 0%,P=0.50),而晶状体睫状体沟切开术组的眼压失败更多(17% vs. 12%,P=0.75)。晶状体睫状体沟切开术组和小梁切除术组的手术失败率无差异(6% vs. 5%,P=1.00),在控制协变量后依然如此。两组最终视力无统计学差异。
晶状体睫状体沟切开术和小梁切除术在12个月时均使眼压显著降低,视力得到改善,成功率相当。小梁切除术组眼压的中位数百分比降低值在统计学上更大,但两种手术在12个月时的平均眼压相当。